about
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging drugs for Hodgkin's lymphoma.
@en
Emerging drugs for Hodgkin's lymphoma.
@nl
type
label
Emerging drugs for Hodgkin's lymphoma.
@en
Emerging drugs for Hodgkin's lymphoma.
@nl
prefLabel
Emerging drugs for Hodgkin's lymphoma.
@en
Emerging drugs for Hodgkin's lymphoma.
@nl
P2093
P2860
P1476
Emerging drugs for Hodgkin's lymphoma.
@en
P2093
Boris Böll
Peter Borchmann
Volker Diehl
P2860
P304
P356
10.1517/14728214.2010.505602
P407
P577
2010-07-15T00:00:00Z